Evidence map›Paper›PMID 33169111›Full record

ArticleOne health outlook2020

Spillover of ebolaviruses into people in eastern Democratic Republic of Congo prior to the 2018 Ebola virus disease outbreak.

Tracey Goldstein, Manjunatha N Belaganahalli, Eddy K Syaluha, Jean-Paul K Lukusa, Denise J Greig, Simon J Anthony, Alexandre Tremeau-Bravard, Riddhi Thakkar, Adrian Caciula, Nischay Mishra and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in One health outlook, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Tracey GoldsteinOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Manjunatha N BelaganahalliOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Eddy K SyaluhaMountain Gorilla Veterinary Project Inc, Goma, Democratic Republic of the Congo.
Jean-Paul K LukusaMountain Gorilla Veterinary Project Inc, Goma, Democratic Republic of the Congo.
Denise J GreigOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Simon J AnthonyCenter for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032 USA.
Alexandre Tremeau-BravardOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Riddhi ThakkarCenter for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032 USA.
Adrian CaciulaCenter for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032 USA.
Nischay MishraCenter for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032 USA.
W Ian LipkinCenter for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032 USA.
Jasjeet K DhanotaOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Brett R SmithOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Victoria M OntiverosOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Nistara RandhawaOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Michael CranfieldOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Christine K JohnsonOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Kirsten V GilardiOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
Jonna A K MazetOne Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California, USA.
University of California, Davis · USColumbia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe second largest Ebola virus disease (EVD) outbreak began in the Democratic Republic of Congo in July 2018 in North Kivu Province. Data suggest the outbreak is not epidemiologically linked to the 2018 outbreak in Equateur Province, and that independent introduction of Ebola virus (EBOV) into humans occurred. We tested for antibodies to ebolaviruses in febrile patients seeking care in North Kivu Province prior to the EVD outbreak.

methodsPatients were enrolled between May 2017 and April 2018, before the declared start of the outbreak in eastern DRC. Questionnaires were administered to collect demographic and behavioural information to identify risk factors for exposure. Biological samples were evaluated for ebolavirus nucleic acid, and for antibodies to ebolaviruses. Prevalence of exposure was calculated, and demographic factors evaluated for associations with ebolavirus serostatus.

resultsSamples were collected and tested from 272 people seeking care in the Rutshuru Health Zone in North Kivu Province. All patients were negative for filoviruses by PCR. Intial screening by indirect ELISA found that 30 people were reactive to EBOV-rGP. Results were supported by detection of ebolavirus reactive linear peptides using the Serochip platform. Differential screening of all reactive serum samples against the rGP of all six ebolaviruses and Marburg virus (MARV) showed that 29 people exhibited the strongest reactivity to EBOV and one to Bombali virus (BOMV), and western blotting confirmed results. Titers ranged from 1:100 to 1:12,800. Although both sexes and all ages tested positive for antibodies, women were significantly more likely to be positive and the majority of positives were in February 2018.

conclusionsWe provide the first documented evidence of exposure to Ebola virus in people in eastern DRC. We detected antibodies to EBOV in 10% of febrile patients seeking healthcare prior to the declaration of the 2018-2020 outbreak, suggesting early cases may have been missed or exposure ocurred without associated illness. We also report the first known detection of antibodies to BOMV, previously detected in bats in West and East Africa, and show that human exposure to BOMV has occurred. Our data suggest human exposure to ebolaviruses may be more frequent and geographically widespread.

Indexed as

Bombali virusEastern DRCEbola virusEbola virus diseaseEbolavirus serologyZoonosis

Identifiers

PMID33169111
PMCPMC7609368
OpenAlexW3096807069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.